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Abstract 
Secondary plant metabolites are evolutionary-designed molecules that interact with multiple biological 
targets in human organisms. Identification of pharmacologically active phytochemicals is usually a time 
consuming and costly process. Cellular membrane affinity chromatography (CMAC) allows the detection of 
secondary metabolites present in complex natural matrices, e.g. plant extracts and their interactions with 
the immobilized fully-functional transmembrane proteins. After the isolation process of the binding 
compounds, CMAC columns can be used to study the binding process between the potential new ligands 
and the immobilized transmembrane protein target. The following parameters can be determined using 
CMAC columns: binding affinity (Kd), association rate constant (kon), dissociation rate constant (koff) and the 
equilibrium constant for complex formation (K). This review summarizes the preparation steps and the use 
of CMAC columns in the drug discovery process of new potential drug leads present in complex natural 
matrices.  
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Introduction 
For thousands of years, humankind has relied on remedies obtained from nature, mostly from plants. 
Secondary plant metabolites can be considered as evolutionary designed drugs, that have evolved as a 
means of herbal communication with other organisms. Plants use the array of phytochemicals that serve 
multiple purposes, for example: protection from abiotic stress, like excessive UV radiation (polyphenols, 
terpenes and terpenoids), attraction of pollinators (volatile terpenes), warding off herbivores (noxious 
phytochemicals, e.g. alkaloids), protection from bacterial or fungal infections (polyphenols, terpenoids, etc) 
[1-4]. Herbivores evolved different forms of biochemical changes, that protect them from the deleterious 
effects of some of the phytochemicals, for example: CYP450 superfamily of enzymes, transporter proteins 
and stress-response cellular signalling pathways [1-4]. Many of these mechanisms are highly conserved 
adaptive stress response systems that humans share with simple herbivores. Numerous secondary 
ADMET & DMPK 6(3) (2018) 200-214 Cell membrane affinity chromatography in drug discovery 
doi: 10.5599/admet.535 201 
metabolites can be considered as already optimized drug leads targeting specific receptors, enzymes or 
biochemical processes [5]. The huge potential of plant-derived drugs is exemplified by numerous secondary 
plant metabolites currently used in clinics, for example, artemisinin, ivermectin, morphine, digitoxin, 
vincristine, podophyllotoxin, and many others [6].  
Unfortunately, plants do not reveal their secrets easily as the identification of pharmacologically active 
phytochemicals is usually a difficult and time-consuming process [7]. Many pharmaceutical companies have 
abandoned drug discovery from natural products, considering it as a demanding high resource 
commitment and often leading to disappointing results (identification of known compounds and poor 
biological activity). Technical problems also prevent now-commonly used high-throughput screening (HTS) 
techniques from testing complex natural matrices for pharmacologically active compounds [8]. HTS 
techniques are designed to test huge libraries of individual compounds. In cases of complex samples, only a 
simple answer would be delivered if the HTS approach was used: the extract is active or not active. 
Identification of pharmacologically active metabolites would have to follow the HTS approach.  
In the traditional approach to drug discovery from natural samples, the first step usually involves the 
isolation of individual compounds. This step often leads to obtaining compounds which are easily isolated 
with reasonable quantities needed to run biological activity assays. The most abundant secondary 
metabolites are usually isolated and many of them have already well-established and known 
pharmacological activity profiles [7]. The use of bio-guided fractionation has provided some solutions by 
narrowing down the isolation process to subfractions that have been identified as having the highest 
activity. However, bio-guided fractionation still requires repetitive multiple steps to identify the 
subfractions that are rich in biologically active compounds.  
Different attempts have been made to shorten the process of drug lead identification from plant 
extracts. Many of these attempts focused on developing target-oriented assays enabling identification of 
compounds with desired activity. Secondary metabolites act by interacting with numerous targets in the 
human body, for example, cytosolic proteins or transmembrane receptors [5]. These new assays are 
designed to screen complex matrices and identify compounds that selectively interact with the biological 
target (enzyme, receptor) [7]. Development of target-oriented assays with immobilized functional enzymes 
has been more popular than the attempts to design tests aimed at identification of compounds targeting 
cell membrane proteins. Cytosolic proteins are usually covalently bonded using their N- or C-terminus 
groups forming the covalent bond with chemical moieties on the surface of the assay scaffold, e.g. the 
inside of the column or magnetic beads [9, 10]. Many natural compounds target cell membrane proteins 
but the solutions developed for cytosolic proteins cannot be used to immobilize transmembrane proteins 
[7]. This review focuses on the development of novel bioassays with the immobilized fully functional cell 
membrane proteins and their use in drug leads discovery from complex natural matrices.  
One of the most important issues in developing assays targeting transmembrane receptors is to make 
sure functional protein is immobilized. Introducing chemical changes in the immobilization process of 
enzymes may lead to irreversible modifications to protein structure and result in failure to develop 
functional assay [11]. It is important to keep boundary lipids surrounding the transmembrane protein 
intact as the subtle interactions between transmembrane domains and these lipids influences how the 
potential ligands bind to the protein. It must be remembered that in the process of transmembrane 
protein immobilization, the cell membrane fragments and not the pure proteins are immobilized [7]. 
Stripping off the boundary lipids would not only lead to changing the receptor binding activity but also 
would probably result in the immobilization of protein aggregates, that would form during the 
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immobilization process [11]. The aggregates would develop because nonpolar amino acid residues, forming 
the transmembrane domains would bury in the interior of the aggregates not to get exposed to an 
aqueous environment. The immobilization of cell membrane fragments with functional transmembrane 
receptors can be achieved in the process of cellular membrane affinity chromatography (CMAC) column 
preparation [11]. Successful immobilization of transmembrane fragments will result in obtaining an assay 
that enables the study of ligand-receptor interactions in close to physiological conditions (Figure 1).  
Cellular membrane affinity chromatography columns – a short historical perspective 
To the best of our knowledge, Lundahl’s group was the first to successfully immobilize transmembrane 
protein, the glucose transporter, GLUT 1 [12]. This study stimulated Wainer’s group to approach the 
immobilization process of nicotinic acetylcholine receptors (nAChRs) on lipid monolayers [13]. Interestingly 
α3β4 nAChRs were also successfully immobilized on the immobilized artificial membrane (IAM) stationary 
phase, developed by Pidgeon et al. [14] and currently available from Regis Technologies, Figure 2. 
 
Figure 1. Cellular membrane affinity chromatography column contains cell membrane fragments with fully 
functional transmembrane protein (TPM) targets and therefore allows for studying the interactions between 
small molecules and TMP in close to physiological conditions 
Studies by the Wainer group showed that CMAC prepared with the use of IAM particles were 
characterized by better reproducibility compared to liposomal columns [13]. Since the successful 
immobilization of nAChRs on the IAM stationary phase, multiple transmembrane proteins have been used 
to prepare CMACs with IAM.PC (immobilized artificial membrane phosphatidylcholine). The examples of 
transmembrane proteins immobilized on IAM.PC particles include: ligand-gated ion channels (xy nAChR x 
= 3,4,7; y = 2,3,4; GABAA, NMDA, combination of nAChR, NMDA) [11, 13, 15-30], G-protein coupled 
receptors (opioid, -adrenergic, P2Y1, Histamine 1-4, CB1, CB2) [31-35] and drug transporters (ABC: Pgp, 
MRP1, MRP2, BCRP; SLC: hOCT and hOCT SNPs, hOAT) [36-39]. IAM.PC mimics the cell membrane 
environment and keeps the experimental conditions close to the physiological state. The surface of the 
IAM.PC stationary phase still contains residual silanol and amine groups on its surface, which may become 
charged during the analysis, resulting in changed retention parameters of the studied ligands. A new class 
of stationary phase has been developed by Regis, IAM.PC.DD2 particles with amine groups endcapped, 
Figure 2. The endcapping leads to an increase of the stationary phase stability and its lipophilicity. To the 
best of our knowledge, there are no data available on the possible use of IAM.PC.DD2 particles in the 
preparation of CMACs. Future experiments should determine whether endcapping the residual amine and 
silanol groups would result in more reproducible data generated with CMACs.  Possible problems with the 
use of more lipophilic artificial membrane particles are discussed further in this review. 
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Figure 2. Differences in surface chemistry of IAM.PC and IAM.PC.DD2 particles. With permission from Regis 
Technologies 
Another approach developed to study ligand-protein interactions involves the use of activated silica for 
the adsorption of cell membrane fragments and is called cell membrane chromatography (CMC) [40]. The 
use of silica introduces silica groups in the process of studying ligand-protein interactions, which does not 
closely resemble physiological conditions. However, numerous drug discovery approaches utilizing CMCs 
have been reported in the literature, for example [40-43]. This review purely focuses on the approach with 
the artificial membrane as the support for the adsorbing cell membrane fragments and therefore CMC is 
not further discussed in this paper.  
Preparation steps of cellular membrane affinity chromatography columns 
The process of preparing CMAC columns has been described in detail elsewhere by Moaddel and 
Wainer [11]. In this review, critical steps of column preparation are described and particular attention is 
paid to issues that have the most critical impact on the process of developing a functional CMAC. The 
process of CMAC development can be divided into 5 consecutive steps: (1) transmembrane protein source 
cell/tissue homogenization, (2) solubilization, (3) dialysis and immobilization, (4) packing and (5) column 
characterization (Figure 3). 
Homogenization 
 The first step in preparing a CMAC column is the choice of transmembrane protein source (cell line 
or tissue). If CMAC is to be used in the drug discovery screening process of complex natural matrices then 
the use of transfected cell line overexpressing the transmembrane protein of choice is recommended. A 
CMAC column prepared with a transfected cell line will result in a higher number of active sites increasing 
the capacity and selectivity of the new column [11]. However, if the experiments using CMAC focus on the 
characterization of transmembrane protein and its interaction with particular ligands, the use of a native 
cell line is advised. The use of native cell line guarantees that the studied protein is surrounded by the 
boundary lipids that assure its full natural functionality. In native cell lines, transmembrane proteins also 
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may undergo some specific post-translational modifications that may not take place in the case of a 
transfected cell line. 
 
Figure 3. Preparation steps of cell membrane affinity chromatography columns (CMAC) 
The homogenization process is performed in a buffered environment (usually Tris -HCl buffer, 50 mM, 
pH 7.4) with the addition of salts, to keep it close to physiological conditions and protect the 
transmembrane protein from degradation. The homogenization procedures are performed on ice and all 
centrifugation steps are executed at 4°C. Glass-dounce homogenizers, polytron homogenizers or sonicators 
are commonly used in the process of cell homogenization [11]. The use of protease and peptidase 
inhibitors is required to immobilize functional transmembrane protein. The choice of proper inhibitors 
depends on the type of cell line used in the experiments. The number of cells used in the experiment 
depends on the level of protein expression and may vary from 1 million to 50 million cells per pellet. After 
rupturing the cell structure, the resulting homogenate is centrifuged at low speed to remove nuclei and the 
pellet is discarded. The remaining supernatant is subsequently centrifuged at high speed and the pellet 
containing cell membranes is collected. In some cases, the use of additional reagents is required for 
immobilization of functional protein. For example, the addition of glycerol enhances the stability of the 
protein in aqueous solutions and was found to be useful in some CMAC preparation protocols [11]. As 
previously mentioned the interactions of protein transmembrane domains with boundary lipids influences 
the activity of the protein. The addition of some phospholipids in the buffer solutions may be required in 
some instances, as previously reported [11]. For more experimental details please refer to the manuscript 
by Moaddel and Wainer [11].  
Solubilization 
The protein isolation is completed using the solubilization step. As in the previous homogenization 
stage, all the experiments are performed at low temperature (4°C) in a buffered environment. Compared 
to the homogenization buffer, used in step 1, solubilization buffer contains detergent, that solubilizes 
transmembrane proteins by forming micelles around them. Several parameters need to be considered 
when choosing the detergent. Again, it is of crucial importance to remember that the goal is to immobilize 
cell membrane fragments with transmembrane proteins and not the purified proteins. The use of strong 
detergents, like Tween or Triton X-100, should be avoided as it may lead to stripping off the boundary 
lipids resulting in the immobilization of nonactive proteins or protein aggregates. These detergents would 
also cause problems in the next step, that requires elimination of the detergent, as they are difficult to 
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remove using dialysis. Previous studies have shown the use of the following detergents results in the 
immobilization of functional transmembrane proteins: sodium cholate (optimal for immobilization of 
ligand-gated ion channels), CHAPS (works well with GPCRs), and β-octyl glucopyranoside [11]. The pellet 
collected after the completion of the homogenization step is mixed with the solubilization buffer and left 
overnight on the orbital shaker at a temperature of 4°C. 
Dialysis and immobilization  
After the completion of the overnight solubilization step, the mixture is centrifuged at high speed and 
the pellet discarded. At this point, the cell membrane fragments are in the supernatant “trapped” in the 
micelles formed by the detergent. The resulting supernatant is put in contact with IAM.PC particles and left 
on the orbital shaker for 1 hour. To complete the process of immobilization of the cell membrane 
fragments on the IAM particles, the mixture containing IAM.PC stationary phase and micelles are placed in 
dialysis tubing and dialysed for 48 hours, to get rid of the detergent. Disruption of micelles results in 
freeing the cell membrane fragments and the phospholipids forming cellular bilayer adsorb on IAM 
particles to protect lipophilic carbon tails from their exposure to the aqueous environment.  
Packing 
After completing the dialysis step the content of the dialysis tubing is centrifuged at low speed and the 
supernatant is discarded. The remaining pellet is washed three times with ammonium acetate buffer (10 
mM, pH 7.4). Ammonium acetate buffer is used also as running buffer, as it is compatible with mass 
spectrometers, commonly used as detectors in subsequent experiments involving the use of CMAC. The 
use of Tris-HCl buffer would result in an additional Tris peak (m/z 122.1, positive ionization mode) in the 
chromatograms. Following the three washes, the pellet is suspended in 1 mL of ammonium acetate buffer 
and packed in a glass column to produce a transmembrane protein IAM.PC CMAC column TMP-CMAC 
(Figure 4). The packing procedure is a low-pressure packing and therefore does not require any 
sophisticated equipment. The packing process resembles the slurry pack procedure used in classical 
column preparation for the isolation of secondary metabolites, but on a smaller scale. After packing the 
column should be washed with running buffer (ammonium acetate, 10 mM, pH 7.4) at the flow rate of 
approximately 0.2 ml/min.  
Column characterization and usage 
After completing all the preparation steps, the moment of truth comes: testing the column to check if 
functional receptors are immobilized on the surface of the IAM particles. This can be achieved through 
several experimental ways. Firstly, the immobilization of transmembrane proteins onto IAM particles can 
be confirmed using confocal microscopy [44]. IAM with immobilized cell membrane fragments is incubated 
with a ligand known to bind to the target protein. The ligand used in the study should contain 
fluorochrome for the identification with the confocal microscope. IAM particles should also be co-
incubated with a series of concentrations of another ligand, binding to the same site of the investigated 
receptor, to confirm the competitive displacement of the ligand containing fluorochrome.  
In another set of experiments confirming the immobilization of functional receptors onto IAM particles 
an artificial mixture of known binders and non-binders is injected onto the column. Known binders should 
be retained on the column with the immobilized receptors significantly longer compared to a negative 
control column CMAC (-). The concept of negative control columns is fully explained in the next section of 
this article discussing the use of CMAC columns in drug discovery from natural samples.  
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Figure 4. Cell membrane affinity chromatography column after packing IAM particles with the immobilized 
cell membrane fragments into a glass column  
Finally, a series of concentrations of a known high-affinity ligand should be injected in consecutive runs 
onto the CMAC column to determine the compound’s binding affinity (KD) [11]. The binding affinity value is 
obtained using frontal affinity chromatography (FAC) and a detector sensitive enough to detect the marker 
ligand at the used concentration. Mass spectrometers are most commonly used in this approach, but any 
other detector suitable for the detection of the marker ligand may be applied. The concept of frontal 
affinity chromatography was thoroughly reviewed in the paper by Ng et al. [45] and will only be shortly 
discussed in this review. Frontal affinity chromatography is a biophysical method to study the interactions 
between a ligand present in the mobile phase and the immobilized target molecule, e.g. a receptor [45]. A 
known marker ligand (for example epibatidine for nAChRs) at constant concentration is run through the 
column with the immobilized transmembrane protein, producing a characteristic sigmoidal breakthrough 
curve (Figure 5). At the beginning of the analysis, the number of available binding sites (immobilized 
transmembrane protein) is higher than the number of the titrating molecules of the marker ligand (the flat 
bottom portion of the curve). After all the binding sites are saturated with the ligand, the concentration of 
the ligand leaving the column gradually increases producing the breakthrough. At the end of the analysis, 
the concentration of the ligand entering and eluting from the column is identical as illustrated by the 
plateau portion of the curve. The inflexion point depends on the ligand concentration, the number of 
available binding sites and the compound’s binding affinity [45]. Typical chromatograms using FAC 
obtained for orthosteric (a) and allosteric (b) nAChR binding sites are presented in Figure 5 [30]. 
Using frontal affinity chromatography with CMAC columns was proved not only to be useful in 
characterization and studies involving the orthosteric but also with the allosteric binding sites of the 
immobilized transmembrane protein [30]. Frontal displacement chromatography can be applied to 
determine the binding affinity of unknown ligand binding to the same site as the marker ligand. It is done 
by injecting constant concentration of the marker ligand with varying concentrations of the studied 
displacer and using the following equation [11]:   
-1 
where: [Dis] – concentration of the displacer; V – retention volume of the marker ligand, when its specific 
concentration is completely suppressed, e.g. by a high concentration of the displacer; KdDis – dissociation 
constant of the displacer; P – product of the Bmax (the number of the available binding sites) and 
(KdDis/Kdmarker), Kdmarker – dissociation constant of the marker ligand [11]. 
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Figure 5.  Frontal chromatograms of (a) increasing concentrations of [
3
H]-epibatidine (A =240 pM, B=150 pM, 
C=100 pM, D=80 pM and E=60 pM) on the α3β4α5 nicotinic receptor column and (b) increasing concentrations 
of mecamylamine on α3β4 nicotinic receptor column. For details please refer to the paper by Ciesla et al. [30]. 
With permission from [30] 
This approach was for example used to determine Kd values of several alkaloids binding to 34 and 
345 nicotinic receptors [30].  
Another chromatographic mode that can be used to study interactions between the adsorbed 
transmembrane receptors and ligands is nonlinear chromatography [11]. In this approach, the investigated 
small molecular compounds are injected onto a CMAC column close to, or at target saturation. The 
observed peak asymmetry allows the study of the kinetics and thermodynamics of interaction between the 
ligands and immobilized protein target. CMAC columns can be used as a first step to identify 
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pharmacologically active secondary metabolites from natural mixtures and after isolation of these 
compounds, they can be applied to obtain pharmacokinetic and pharmacodynamic data.  
In zonal chromatography, a small amount of the ligand is loaded onto the column and this allows for 
ranking the affinity of the investigated compounds [11].  
The use of CMACs in identification of pharmacologically active metabolites from natural mixtures 
In the early reports of CMAC column usage, the columns were applied to the study of the binding 
characteristics of the immobilized transmembrane proteins [7]. However, CMAC columns can be 
successfully applied in the process of identification of pharmacologically active compounds present in 
complex natural matrices targeting transmembrane receptors [7, 46]. There are several issues that need to 
be taken into consideration when applying CMACs in drug discovery from natural samples. The first 
decision that has to be made is in choosing extracts that will be screened using the newly developed 
bioassay. The samples to be run on the CMAC columns should not be random, but carefully selected. Plant 
extracts that previously were reported to exert desired pharmacological activity may be considered for the 
screening experiments. However, the observed biological effect may not be from the result of the 
interaction of secondary metabolites present in the extract and the targeted protein, immobilized on the 
artificial membrane support. Another idea of narrowing down the possible screening extract candidates is 
to use a simple in vivo model (C. elegans or D. melanogaster) and test the extracts for biological activity. 
The extracts that exert the biological effect are further screened to identify phytochemicals responsible for 
this effect. Again, there has to be a known, or at least a rightfully hypothesized connection between 
activation/inhibition of the targeted transmembrane protein and pharmacological activity tested in the in 
vivo model. The easiest way to check for the possible presence of phytochemicals interacting with the 
transmembrane receptors is to use frontal affinity chromatography and a marker ligand known to bind to 
the transmembrane receptor [7, 30]. The displacement observed after co-injecting the analysed extract 
and the marker ligand would indicate the presence of phytochemicals competing with the marker for the 
binding site. This approach can be applied to screen extracts for compounds interacting with both 
orthosteric and allosteric binding sites. Figure 6 presents the displacement of mecamylamine, a known 
nAChR allosteric inhibitor displaced by Lycopodium clavatum L. extract on CMAC columns with immobilized 
two types of nicotinic receptors α3β4 and α3β4α5 [30].  
The identification process of individual secondary metabolites responsible for the observed 
displacement of the marker ligand is performed using the “missing peak chromatography” approach [46]. 
One of the greatest challenges in drug discovery from plant extracts, using CMAC columns, is discerning 
specific interactions (phytochemicals interacting with the immobilized transmembrane target) from 
nonspecific interactions (compounds interacting with IAM particles or other transmembrane proteins co-
immobilized with the studied targeted receptor). Lipophilic compounds have been found to be strongly 
retained on IAM.PC particles and an alternative approach has been proposed to study such ligands: 
immobilization of cell membrane fragments onto the surface of an open tubular capillary (OT columns) [7]. 
For example, OT columns were successfully used to immobilize cell membrane fragments with CB1/CB2 
receptors and further for the identification of endocannabinoid receptor ligands from the extract of 
Zanthoxylum clava-herculis L. [34, 47]. The development and the use of OT columns remain beyond the 
scope of this review and interested readers are encouraged to refer to other publications [7]. Co-
immobilization of other proteins does not need to be considered as a CMAC disadvantage, as the same 
column can be utilized to study compounds binding to multiple transmembrane proteins [28]. To 
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characterize multiple proteins co-immobilized on the IAM particles, different marker ligands have to be 




Figure 6. Frontal elution profile of 1 µM mecamylamine (I) and 1 µM mecamylamine + 5% Lycopodium 
clavatum (ii) on (a) the α3β4 nicotinic receptor column and (b) α3β4α5 nicotinic receptor column. For details 
please refer to the paper by Ciesla et al. [30]. With permission from [30]. 
The missing peak chromatography approach requires the use of a negative control CMAC column, 
CMAC(-). As previously stated, transfected cell lines stably overexpressing studied transmembrane proteins 
are recommended for the preparation of CMAC columns. A negative control column (CMAC(-)) is prepared 
using the same cell line, however not expressing the receptors overexpressed by the transfected line. For 
example, in the case of nAChR CMAC columns, HEK cells overexpressing desired nAChR subtypes were used 
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to prepare CMAC(+), while HEK 293 cells were utilized to develop CMAC(-) [30]. In the missing peak 
chromatography technique, plant extracts are chromatographed on CMAC(+) and CMAC(-) columns using 
ammonium acetate buffer (10 mM, pH 7.4) delivered at 0.2 ml/min as mobile phase [46]. Fractions are 
collected based on the observed chromatograms. The obtained fractions are subsequently fingerprinted on 
C18 columns and the fingerprints obtained using CMAC(+) and CMAC(-) are compared. The difference 
between the CMAC(+) and CMAC(−) columns is in the availability of the immobilized protein target.  The 
differences in the retention of a compound on the CMAC(+) column relative to the CMAC(−) column is due 
to specific interactions with the target [7, 46]. A peak that is missing in the fingerprint of a CMAC(+) early 
fraction, but present in the control and corresponding CMAC(−) early fraction, is considered to bind to the 
immobilized transmembrane protein target on the CMAC(+) column [46]. Elution of this particular 
compound in a later fraction of CMAC(+), along with its absence in the corresponding fraction in CMAC(−), 
is a further confirmation of the affinity of this compound for the targeted transmembrane receptor in 
CMAC(+) [46]. Compounds identified as specifically binding to the studied receptors can be subsequently 
isolated using analytical or semipreparative HPLC, their structures elucidated and further tested in 
functional assays or in vivo models.  
CMAC chromatography columns with immobilized cell membrane fragments on IAM particles do not 
solve all of the problems in the drug discovery process from natural samples. This approach requires the 
use of negative control columns and the solvent choice is limited to buffered aqueous solvents (with only 
up to approx. 10% of organic modifier). CMAC columns, however, do speed up the process of target 
identification, without the need to isolate individual compounds and test them separately using different 
assays. CMAC is an assay, in which transmembrane proteins remain submerged in a natural lipid 
environment, in close to physiological conditions. CMAC columns allow for the identification of compounds 
binding to receptor subtypes. After identification and isolation of pharmacologically active phytochemicals, 
CMAC columns may be used to study their interaction with the immobilized protein target (obtaining 
pharmacodynamics and pharmacokinetic data). The drug discovery process with CMACs is a target-
oriented technique, ideally suited for creating libraries of natural compounds interacting with a specific cell 
membrane target.  
Future directions 
 The potential of cell membrane affinity chromatography columns in the drug discovery process 
from natural samples has been underestimated. Pharmaceutical companies have focused their discovery 
programs on automated high-throughput screening techniques (HTS), which are not suitable for complex 
matrices. However, the introduction of HTS techniques did not result in the predicted substantial increase 
of new classes of drugs entering the market [8]. Secondary metabolites are evolutionary-designed 
compounds targeting specific, often highly-conserved signalling pathways and are already optimized to be 
pharmacologically active. One of the ways of unravelling the mysteries of natural compounds is to develop 
approaches enabling identification of these phytochemicals. Cellular membrane affinity chromatography 
columns allow phytochemists to selectively identify compounds interacting with transmembrane proteins. 
We predict CMAC columns have a potential to become the next generation of drug discovery tools in 
phytochemistry and pharmacology labs. These columns may be easily applied to build libraries of natural 
compounds that can move drug discovery projects forward to the next step.  Some advice is given: 
carefully choose your transmembrane target by closely studying the possible pathways involved in the 
disease. An example is given from our lab: we are interested in cellular signalling pathways that have 
evolved to protect neurons from different forms of biological stress (oxidative, metabolic, proteotoxic or 
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inflammatory stress). Published data indicated that the activation of the BDNF (brain-derived neurotrophic 
factor) pathway is neuroprotective [48]. BDNF works by binding with transmembrane tropomyosin 
receptor kinase (TrkB). A CMAC column with the immobilized TrkB receptors is to be used to screen 
selected plant extracts for natural compounds binding to this receptor and mimicking the neuroprotective 
effects of BDNF. Preparation of CMAC columns appears to be considered as a complicated approach and 
this may prevent it from common use in drug discovery or phytochemistry laboratories. The truth is, the 
preparation of CMAC columns is possible in almost every lab focusing on natural product discovery. Future 
direction may include the development of a kit that would allow interested labs to easily develop a column 
with the immobilized desired transmembrane protein. 
CMAC has a potential to work well with other drug discovery approaches, for example, ligand fishing 
techniques. Pharmacologically active compounds may be first identified using ligand fishing techniques 
followed by ligand-protein interaction studies with a CMAC column.  
The advent of novel drug discovery approaches is needed in this new era when drug discovery from 
natural samples is again becoming popular. The use of old techniques, that were one of the reasons for 
abandoning natural product screening, need to be replaced by innovative assays. Cellular membrane 
affinity chromatography together with ligand fishing techniques have everything that is required to 
become drug discovery techniques of the 21st century.  
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